Search results for " hemorrhage"

showing 10 items of 355 documents

Helicobacter pylori infection does not affect the early rebleeding rate in patients with peptic ulcer bleeding after successful endoscopic hemostasis…

2003

Background and study aims Eradication of Helicobacter pylori infection can reduce the rebleeding rate of peptic ulcer bleeding in the long term. There are few data on the influence of H. pylori on the rebleeding rate in the acute phase of bleeding however. We therefore prospectively investigated the influence of H. pylori infection on the early rebleeding rate in patients who had undergone successful endoscopic hemostasis treatment for peptic ulcer bleeding. Patients and methods Between January 1996 and November 2000 all patients with peptic ulcer bleeding were evaluated consecutively. The diagnosis of H. pylori infection was made at index endoscopy, using histology and the rapid urease tes…

AdultMalemedicine.medical_specialtyPeptic UlcerAdolescentRapid urease testPeptic Ulcer HemorrhageGastroenterologyStatistics NonparametricHelicobacter InfectionsRecurrenceInternal medicineGastroscopymedicineHumansProspective StudiesProspective cohort studyAgedProbabilityAged 80 and overbiologyHelicobacter pyloribusiness.industryHemostasis EndoscopicGastroenterologyHelicobacter pyloriMiddle Agedbiology.organism_classificationSurgeryLogistic ModelsPeptic Ulcer HemorrhageTreatment OutcomeForrest classificationHemostasisFemaleGastritismedicine.symptomComplicationbusinessFollow-Up StudiesEndoscopy
researchProduct

Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion.

2021

Non-cirrhotic portal vein thrombosis (PVT) in patients with antiphospholipid syndrome (APS) is a rare complication, and the management has to be determined individually based on the extent and severity of the presentation. We report on a 37-year-old male patient with non-cirrhotic chronic PVT related to a severe thrombophilia, comprising APS, antithrombin-, factor V- and factor X-deficiency. Three years after the initial diagnosis of non-cirrhotic PVT, the patient presented with severe hemorrhagic shock related to acute bleeding from esophageal varices, requiring an emergency transjugular intrahepatic portosystemic stent shunt (TIPSS). TIPSS was revised after a recurrent bleeding episode du…

AdultMalemedicine.medical_specialtyPortal venous pressuremedicine.medical_treatment030204 cardiovascular system & hematologyThrombophiliaEsophageal and Gastric Varices03 medical and health sciences0302 clinical medicineEsophageal varicesHypertension PortalmedicineHumansThrombophiliaEmbolizationPatient Care TeamVenous Thrombosisbusiness.industryPortal VeinGastroenterologymedicine.diseaseThrombosisSurgeryPortal vein thrombosisPortal hypertension030211 gastroenterology & hepatologyStentsPortasystemic Shunt Transjugular IntrahepaticbusinessVaricesGastrointestinal HemorrhageZeitschrift fur Gastroenterologie
researchProduct

Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis

2014

Background— Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings. Methods and Results— In a randomized, double-blind, double-dummy trial of 2589 patients with acute VTE treated with low-molecular-weight or unfractionated heparin for 5 to 11 days, we compared dabigatran 150 mg twice daily with warfarin. The primary outcome, recurrent symptomatic, objectively confirmed VTE and related deaths during 6 months of treatment occurred in 30 of the 1279 dabigatran patients (2.3%) compared with 28 of the 1289 warfarin patients (2.2%; hazard ratio, 1.08; 95% confidence interval [CI], 0.…

AdultMalemedicine.medical_specialtyRE-COVER IIrecurrenceAntagonists & inhibitorsAdolescentvenous thromboembolismAntithrombinsDabigatranYoung AdultDouble-Blind MethodRisk FactorsPhysiology (medical)Internal medicinemedicineHumansdabigatrancardiovascular diseasesantagonists & inhibitorAgedacute venous thromboembolismHeparinbusiness.industryWarfarinFollow up studiesAnticoagulantsantagonists & inhibitors; hemorrhage; recurrence; thrombin; venous thromboembolism; warfarinHeparinHeparin Low-Molecular-WeightMiddle AgedthrombinSettore MED/11 - Malattie Dell'Apparato CardiovascolarewarfarinHeparin.low molecular weightPooled analysisAnesthesiaAcute Diseasebeta-AlanineBenzimidazolesFemaledabigatran; warfarin; acute venous thromboembolism; RE-COVER IIhemorrhageCardiology and Cardiovascular MedicinebusinessVenous thromboembolismFollow-Up Studiesmedicine.drug
researchProduct

A unique fatal case of Waterhouse–Friderichsen syndrome caused by Proteus mirabilis in an immunocompetent subject

2019

Abstract Introduction: The Waterhouse–Friderichsen syndrome (WFS), also known as purpura fulminans, is a potentially lethal condition described as acute hemorrhagic necrosis of the adrenal glands. It is often caused by infection. Classically, Neisseriae meningitidis represents the main microorganism related to WFS, although, infrequently, also other infectious agents are reported as a possible etiologic agent. The authors report the first case of death due to Proteus mirabilis infection, with postmortem evidence of WFS. Patient concerns: After a facial trauma that provoked a wound on the nose, the subject, a healthy 40-years old man, was conducted to the local hospital (in Sicily, Italy) af…

AdultMalemedicine.medical_specialtySepsiforensic sciencesAutopsyGastroenterologysepsisSepsisImmunocompromised Host03 medical and health sciences0302 clinical medicineSettore MED/43 - Medicina LegaleInternal medicinemedicineWaterhouse–Friderichsen syndromeHumansClinical Case Report030212 general & internal medicineLeukocytosisProteus mirabilisWaterhouse-Friderichsen syndromeDisseminated intravascular coagulationbiology4900business.industryBilateral massive adrenal hemorrhageWaterhouse-Friderichsen syndrome: XGeneral Medicinemedicine.diseasebiology.organism_classificationProteus InfectionProteus mirabilisBilateral massive adrenal hemorrhage; Forensic sciences; Proteus mirabilis infection; Sepsis; Waterhouse-Friderichsen syndrome; Adult; Humans; Male; Proteus Infections; Waterhouse-Friderichsen Syndrome; Immunocompromised Host; Proteus mirabilisProteus mirabilis infection030220 oncology & carcinogenesisForensic sciencemedicine.symptomProteus InfectionsbusinessAdrenal HemorrhageResearch ArticleHumanPurpura fulminansMedicine
researchProduct

Temporal Trends in Sex Differences With Regard to Stroke Incidence

2016

Background and Purpose— We evaluated temporal trends in stroke incidence between men and women to determine whether changes in the distribution of vascular risk factors have influenced sex differences in stroke epidemiology. Methods— Patients with first-ever stroke including ischemic stroke, spontaneous intracerebral hemorrhage, subarachnoid hemorrhage, and undetermined stroke between 1987 and 2012 were identified through the population-based registry of Dijon, France. Incidence rates were calculated for age groups, sex, and stroke subtypes. Sex differences and temporal trends (according to 5-year time periods) were evaluated by calculating incidence rate ratios (IRRs) with Poisson regress…

AdultMalemedicine.medical_specialtyStroke registry030204 cardiovascular system & hematologyVascular riskBrain Ischemia03 medical and health sciencesSex Factors0302 clinical medicineSex factorsEpidemiologymedicineHumansRegistriesStrokeAgedCerebral HemorrhageAged 80 and overAdvanced and Specialized Nursingbusiness.industryIncidenceIncidence (epidemiology)Middle AgedSubarachnoid Hemorrhagemedicine.diseaseStrokePhysical therapyFemaleFranceNeurology (clinical)Cardiology and Cardiovascular MedicineStroke incidencebusiness030217 neurology & neurosurgeryDemographyStroke
researchProduct

Increasing Burden of Stroke: The Dijon Stroke Registry (1987–2012)

2017

<b><i>Background:</i></b> We aimed to provide a representation of the global burden of stroke. <b><i>Methods:</i></b> All cases of stroke were prospectively identified through the population-based registry of Dijon, France (1987–2012). Attack rates and mortality rates (defined as stroke leading to death within 30 days) were standardized to the European standard. Sex differences and temporal trends were evaluated by calculating rate ratios (RRs). <b><i>Results:</i></b> In all, 5,285 stroke cases (52.7% women) were recorded. The standardized attack rate was 98.2/100,000/year and the mortality rate was 12/100,000/year, and…

AdultMalemedicine.medical_specialtyStroke registrySubarachnoid hemorrhageEpidemiologyAttack ratePopulation030204 cardiovascular system & hematologyBrain Ischemia03 medical and health sciencesSex Factors0302 clinical medicineRisk FactorsInternal medicineEpidemiologyPrevalenceHumansMedicineRegistrieseducationStrokeAgedAged 80 and overIntracerebral hemorrhageeducation.field_of_studybusiness.industryIncidenceMortality rateAge FactorsMiddle Agedmedicine.diseaseStrokeSurvival RateFemaleFranceNeurology (clinical)businessIntracranial Hemorrhages030217 neurology & neurosurgeryNeuroepidemiology
researchProduct

Determinants of Case Fatality After Hospitalization for Stroke in France 2010 to 2015.

2019

Background and Purpose— The aims of this study were to (1) describe early and late case fatality rates after stroke in France, (2) evaluate whether their determinants differed, and (3) analyze time trends between 2010 and 2015. Methods— Data were extracted from the Système National des données de santé database. Patients hospitalized for stroke each year from 2010 to 2015, aged ≥18 years, and affiliated to the general insurance scheme were selected. Cox regressions were used to separately analyze determinants of 30-day and 31- to 365-day case fatality rates for each stroke type (ischemic, intracerebral hemorrhage, and subarachnoid hemorrhage). Results— In 2015, of the 73 124 persons hospit…

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageAdolescentDatabases FactualComorbidity030204 cardiovascular system & hematologyCcomorbidityBrain Ischemia03 medical and health sciencesYoung Adult0302 clinical medicineAge DistributionCase fatality ratemedicineHumansHospital MortalityMortalitySex DistributionStrokeAntihypertensive AgentsAgedCerebral HemorrhageAdvanced and Specialized NursingAged 80 and overbusiness.industryMiddle AgedSubarachnoid Hemorrhagemedicine.diseasePrognosisComorbidity3. Good healthStrokeHospitalizationEmergency medicineHypertension[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieFemaleNeurology (clinical)FranceCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryStroke
researchProduct

Aneurysm surgery of patients in poor grade condition. Indications and experience

1994

Out of a total of 196 patients admitted with aneurysmal subarachnoid haemorrhage (SAH) to the neurological department in Mainz over a 42 month period, 48 patients (24.5%) were considered as grade IV or V on admission. Aneurysm surgery within 48 hours after SAH was performed in 56.3% of these patients, 2% were operated between day 3 and 7 and 16.6% were operated after day 7. 25% did not undergo operation because of severe neurological deficit and brain damage. The overall outcome according to the Glasgow outcome scale in the surgically treated group was full recovery in 11.1%, moderate disability in 16.7%, severe disability in 47.2%, vegetative state in 2.8% and death in 22.2%. All patients …

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageBrain damageRisk FactorsmedicineHumansGlasgow Coma ScaleProspective Studiescardiovascular diseasesProspective cohort studyAgedbusiness.industryGlasgow Outcome ScaleGlasgow Coma ScaleIntracranial AneurysmVasospasmGeneral MedicineMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseSurgeryTreatment OutcomeNeurologyFemaleSubarachnoid haemorrhageAneurysm surgeryNeurology (clinical)medicine.symptombusinessNeurological Research
researchProduct

Acute symptomatic seizures in cerebral venous thrombosis

2020

© 2020 American Academy of Neurology

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageInfarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineModified Rankin ScaleRisk FactorsSeizuresInternal medicinemedicineHumans030212 general & internal medicineStrokeIntracerebral hemorrhageVenous Thrombosisbusiness.industrycerebral venous thrombosisSymptomatic seizuresOdds ratioMiddle Agedmedicine.diseaseThrombosisCerebral Veins3. Good healthVenous thrombosisAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)Intracranial Thrombosisbusiness030217 neurology & neurosurgery
researchProduct

Endovascular therapy for vasospasm after aneurysmatic subarachnoid hemorrhage

2016

Balloon angioplasty and/or selective intra-arterial vasodilator therapies are treatment options in patients with vasospasm after subarachnoid hemorrhage (SAH). We analyzed the effect of balloon angioplasty and/or selective intra-arterial vasodilator therapy in our patients.Twenty-six patients (vasodilation group, VDT) were treated with intra-arterial nimodipine. The balloon angioplasty with nimodiopine-group (BAP-N group) comprised 21 patients. The primary endpoint of this study was successful angiographic vessel dilation in vasospastic vessels after balloon angioplasty, together with nimodipine (BAP-N group), compared to intra-arterial vasodilator therapy (VDT group) with nimodipine alone.…

AdultMalemedicine.medical_specialtySubarachnoid hemorrhageVasodilator Agentsmedicine.medical_treatmentCerebral arteriesVasodilationBalloon030218 nuclear medicine & medical imaging03 medical and health sciencesPostoperative Complications0302 clinical medicineInternal medicineAngioplastymedicineClinical endpointHumansVasospasm IntracranialNimodipineAgedRetrospective Studiesbusiness.industryEndovascular ProceduresVasospasmGeneral MedicineCerebral ArteriesMiddle AgedSubarachnoid Hemorrhagemedicine.diseaseTreatment OutcomeInjections Intra-ArterialAnesthesiaCardiologyFemaleNimodipineSurgeryPatient SafetyNeurology (clinical)businessAngioplasty Balloon030217 neurology & neurosurgerymedicine.drugBritish Journal of Neurosurgery
researchProduct